View Item 

Show simple item record

Electrocardiogram Monitoring After the Food and Drug Administration Warnings for Citalopram: Unheeded Alerts?
dc.contributor.authorGerlach, Lauren B.
dc.contributor.authorKim, Hyungjin Myra
dc.contributor.authorYosef, Matheos
dc.contributor.authorKales, Helen C.
dc.contributor.authorHenry, Jennifer
dc.contributor.authorZivin, Kara
dc.date.accessioned2018-11-20T15:34:08Z
dc.date.available2019-10-01T16:02:11Zen
dc.date.issued2018-08
dc.identifier.citationGerlach, Lauren B.; Kim, Hyungjin Myra; Yosef, Matheos; Kales, Helen C.; Henry, Jennifer; Zivin, Kara (2018). "Electrocardiogram Monitoring After the Food and Drug Administration Warnings for Citalopram: Unheeded Alerts?." Journal of the American Geriatrics Society 66(8): 1562-1566.
dc.identifier.issn0002-8614
dc.identifier.issn1532-5415
dc.identifier.urihttps://hdl.handle.net/2027.42/146403
dc.publisherHoughton Mifflin Harcourt
dc.publisherWiley Periodicals, Inc.
dc.subject.othercitalopram
dc.subject.otherEKG
dc.subject.otherFDA warning
dc.titleElectrocardiogram Monitoring After the Food and Drug Administration Warnings for Citalopram: Unheeded Alerts?
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146403/1/jgs15420_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146403/2/jgs15420.pdf
dc.identifier.doi10.1111/jgs.15420
dc.identifier.sourceJournal of the American Geriatrics Society
dc.identifier.citedreferenceDusetzina SB, Higashi AS, Dorsey ER, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Med Care 2012; 50: 466 – 478.
dc.identifier.citedreferenceFDA Drug Safety Communication: Abnormal Heart Rhythms Associated with High Doses of Celexa (Citalopram Hydrobromide). 2011 (online). Available at www.fda.gov/drugs/drugsafety/ucm269086.htm Accessed May 18, 2014.
dc.identifier.citedreferenceFDA Drug Safety Communication: Revised Recommendations for Celexa (Citalopram Hydrobromide) Related to a Potential Risk of Abnormal Heart Rhythms with High Doses. 2012 (online). Available at www.fda.gov/drugs/drugsafety/ucm297391.htm Accessed May 18, 2014
dc.identifier.citedreferenceAstrom‐Lilja C, Odeberg JM, Ekman E, Hagg S. Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008; 17: 587 – 592.
dc.identifier.citedreferenceTampi RR, Balderas M, Carter KV, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics 2015; 56: 36 – 43.
dc.identifier.citedreferenceVieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012; 125: 859 – 868.
dc.identifier.citedreferenceRector TS, Adabag S, Cunningham F, Nelson D, Dieperink E. Outcomes of citalopram dosage risk mitigation in a veteran population. Am J Psychiatry 2016; 173: 896 – 902.
dc.identifier.citedreferencePorsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014; 311: 682 – 691.
dc.identifier.citedreferenceZivin K, Pfeiffer PN, Bohnert AS, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013; 170: 642 – 650.
dc.identifier.citedreferenceCastro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: A cross sectional study of electronic health records. BMJ 2013; 346: f288.
dc.identifier.citedreferenceBeach SR, Kostis WJ, Celano CM, et al. Meta‐analysis of selective serotonin reuptake inhibitor‐associated QTc prolongation. J Clin Psychiatry 2014; 75: e441 – e449.
dc.identifier.citedreferenceGerlach LB, Kales HC, Maust DT, et al. Unintended consequences of adjusting citalopram prescriptions following the 2011 FDA warning. Am J Geriatr Psychiatry 2017; 25: 407 – 414.
dc.identifier.citedreferenceBurk M, Moore V, Glassman P, et al. Medication‐use evaluation with a Web application. Am J Health Syst Pharm 2013; 70: 2226 – 2234.
dc.identifier.citedreferenceDepartment of Veterans Affairs. Updated Guidance: Citalopram Hydrobromide (Celexa) and Dose‐Dependent QT Interval Prolongation. 2011. Available at https://www.healthquality.va.gov/documents/updatenationalpbmbulletin041712final.pdf Accessed October 1, 2015.
dc.identifier.citedreferenceLopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 2017; 46: 348 – 355.
dc.identifier.citedreferenceShadish WR, Cook TD, Campbell DT. Experimental and Quasi‐Experimental Designs for Generalized Causal Inference, 2nd Ed. Boston, MA: Houghton Mifflin Harcourt; 2001.
dc.identifier.citedreferenceBriesacher BA, Soumerai SB, Zhang F, et al. A critical review of methods to evaluate the impact of FDA regulatory actions. Pharmacoepidemiol Drug Saf 2013; 22: 986 – 994.
dc.identifier.citedreferenceWagner AK, Chan KA, Dashevsky I, et al. FDA drug prescribing warnings: Is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006; 15: 369 – 386.
dc.identifier.citedreferenceRasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999; 19: 407 – 415.
dc.identifier.citedreferenceGerlach LB, Kim HM, Yosef M, et al. Assessing responsiveness of health systems to drug safety warnings. Am J Geriatr Psychiatry 2018; 26: 476 – 483.
dc.identifier.citedreferenceKizer KW, Dudley RA. Extreme makeover: Transformation of the veterans health care system. Annu Rev Public Health 2009; 30: 313 – 339.
dc.identifier.citedreferencePhillips MS, Gayman JE, Todd MW. ASHP guidelines on medication‐use evaluation. American Society of Health‐system Pharmacists. Am J Health Syst Pharm 1996; 53: 1953 – 1955.
dc.identifier.citedreferenceLasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215 – 2220.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jgs15420_am.pdf
Size:
4.377MB
Format:
PDF
View/Open
Name:
jgs15420.pdf
Size:
154.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.